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respectively. Within a budget of 10 million RUR the number of
patients at European LDL-C goal at 1 year is: 558 on Crestor,
361 on Vasilip, 385 on Atoris and 394 on Tulip. CONCLU-
SION: Based on the equi-effective dose of statins CRESTOR is
shown to be cost-effective compared to atorvastatin and simvas-
tatin even at low generic prices across all value metrics analysed.
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OBJECTIVES: The purpose of this study was to evaluate health
and economic beneﬁts, throughout the country, as the conse-
quence of the realization cardiovascular system diseases preven-
tion programme among the children and youth of school age in
Poland. METHODS: This was a health and an economic evalu-
ation using a simulation model based on 10,000 subjects. The
frequency of incidence of cardiovascular system diseases was
estimated using data from the Polish epidemiological trials pro-
grams and statistical yearbook. Costs of cardiovascular system
diseases treatment were derived from medical services catalogue
of The National Health Fund (NFZ). The effectiveness of pre-
ventive programmes was extracted from the INTERHEART
study and other published sources. RESULTS: Correctly con-
structed and conducted prevention programme of cardiovascular
system diseases among the children and youth of school age in
Poland could reduce about 70% lipid disorders, 50% obesity,
50% arterial hypertension, 8% heart attack, 5% the diabetes
mellitus type 2, and about 4% the cerebrovascular incident in
adult life of the beneﬁciaries. The indirect results of prevention
are the extending of life-span and the improvement of health
quality of individuals as well as their families, the improvement
of epidemiological situation and measurable ﬁnancial proﬁt
throughout the country because of dangerous and chronic health
complications prevention as well as lack of limitations of ability
to work. CONCLUSION: The cost of analysed preventive pro-
gramme of cardiovascular system diseases is about 15 times
smaller than health care costs of these diseases.
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OBJECTIVES: To perform a health technology assessment
(HTA) commissioned by the German Federal Ministry of Health
on coronary fractional ﬂow reserve (FFR) to guide the decision
on coronary stenting in patients with suspected mild coronary
artery disease (CAD). METHODS: We performed a systematic
literature search to identify clinical and economic studies on
FFR-guided strategies. A meta-analysis on the diagnostic value of
FFR and a review on economic evaluations were done. We devel-
oped a decision-analytic Coronary Artery Disease Outcome
Model (CADOM) for the German health care context. Patients
with angiographically suspected CAD without conﬁrmed diag-
nosis were modeled in subgroups for age and gender (basecase:
60-year old man). Model parameters were derived from German
databases and the published literature. We adopted the societal
perspective, used a life-time horizon, and discounted costs and
effects by 5% per year. RESULTS: We identiﬁed 10 diagnostic
accuracy studies, 1 multicenter randomized clinical trial (RCT)
for efﬁcacy, and 1 decision-analytic cost-effectiveness study (US
context). Pooled sensitivity and speciﬁcity of FFR was 81.7%
(95%CI: 77.0–85.7%) and 78.7% (95%CI: 74.3–82.7%),
respectively. Few studies used a sufﬁcient goldstandard. The RCT
investigated the efﬁcacy of a FFR-based treatment strategy and
showed advantages for patients in terms of major adverse cardiac
events and freedom from angina. The cost-effectiveness study
showed the FFR-based strategy being cost-saving in the US health
care system. Results from German CADOM indicated a gain in
(quality-adjusted) life-expectancy for the FFR-guided strategy
compared to universal coronary intervention in all patients. The
base-case discounted incremental cost-effectiveness ratio was
Euro 16,000 per QALY gained. Uni- and multivariate sensitivity
analyses showed robust results. CONCLUSION: This HTA sug-
gests that FFR-guided treatment results in clinical beneﬁts for
patients with suspected CAD and should be cost-effective in the
German context. FFR should be implemented in routine clinical
decision making in patients with suspected CAD.
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OBJECTIVES: The phenomena of response-shift has recently
entered the PRO literature and provided new insight how change
scores in PRO measures such as HRQL-instruments can be inter-
preted. Methods have been provided to investigate the 3 types of
response-shift: recalibration, reconceptualization and reprioriti-
zation. The aim of this study was to investigate to what extend
response-shift occurs in individualized vs. disease-speciﬁc
HRQL-instruments and how it can be captured. METHODS: In
a prospective longitudinal study 100 patients with angiographi-
cally documented coronary artery disease were approached at 2
time points (hospital-baseline and 6 month-follow-up) with an
individualized QoL-instrument (Schedule for the Evaluation of
Individualized Quality of Life; SEIQOL) and a disease-speciﬁc
HRQL-instrument (MacNew Heart Disease Quality of Life
Questionnaire; MacNew). The SEIQoL is constructed allowing
capturing two aspects of response-shift: reconceptualization
(cues) and reprioritization (weights). In addition the “Then-Test”
was applied to the MacNew at 6 month-follow-up to capture
recalibration. RESULTS: Informed consent was given by 64
patients (61+/-7.5 years, 28.1% female, main symptom: 71.9%
angina) and all patients were treated with percutaneous coronary
interventions. 71.9% returned the six-month follow-up. Indi-
vidualized QoL (SEIQoL-Index) did not improve over the 6
month-period (t0: 65.8+/-25.5; t1: 67.8+/-20.5, p = ns), in addi-
tion 25% of the participants showed response-shift effects of
reconceptualization in at least one cue of the SEIQoL. No sig-
niﬁcant change in SEIQoL cue-weights occurred. Disease-speciﬁc
HRQL scores changed signiﬁcantly over time (t0: 4.7+/-1.2, t1:
5.3+/-1.1, p = 0.004); and no recalibration occurred (t0-then-
test: 4.6+/-1.4, p = 0.418). CONCLUSION: This prospective
study investigating the effects of percutaneous coronary interven-
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